AFREZZA™
AFREZZA™ is a novel, ultra rapid acting mealtime insulin therapy being studied for use in adult patients with type 1 and type 2 diabetes mellitus for the treatment of hyperglycemia. It is a drug-device combination product, consisting of AFREZZA Inhalation Powder pre-metered into single use dose cartridges and the light, discreet and easy to use AFREZZA Inhaler. A new drug application (NDA) requesting approval to market AFREZZA was accepted by the FDA in May 2009.
We believe that AFREZZA is able to satisfy diabetes patients’ needs by being highly synchronized with the normal digestion of a typical meal. We believe that because of its unique pharmacokinetic profile, AFREZZA may be a promising new therapy for patients.
- A significant reduction in post-meal glucose fluctuations, which are believed to be an important risk factor in the development of complications
- The ability to achieve comparable levels of overall glucose control compared with present "state-of-the-art" treatment
- A lower risk of hypoglycemia, which is considered to be a major problem for patients
- Did not observe the weight gain typically associated with other insulin treatments
